Ablynx's anti-vWF Nanobody achieves clinical proof-of-concept in Phase II TITAN study

First-in-class potential with orphan drug status for the treatment of acquired thrombotic thrombocytopenic purpura

18-Jun-2014 - Belgium

Ablynx announced that it has achieved positive results in the Phase II TITAN study with the anti-vWF Nanobody®, caplacizumab, in patients with acquired thrombotic thrombocytopenic purpura (TTP), a rare disorder of the blood coagulation system that causes microthrombi to form which can block small blood vessels throughout the body. Treatment with caplacizumab plus standard of care resulted in a statistically significant reduction in time to confirmed normalisation and was associated with fewer exacerbations and more complete remissions as compared to patients receiving the standard of care plus placebo.

The worldwide Phase II TITAN clinical trial was a single-blinded, randomised, placebo-controlled study which recruited from January 2011 to January 2014. In total, 75 patients were randomized on a 1:1 basis with one active drug treatment arm and one placebo arm. All patients received the current standard of care which is primarily multiple plasma exchanges. The protocol for the study was adapted in September 2013, to also allow one day of plasma exchange prior to study enrolment. Those patients in the active drug treatment arm immediately received an intravenous bolus dose of 10 mg caplacizumab and then a 10 mg subcutaneous dose of the drug daily until 30 days had elapsed after the final plasma exchange. Patients in the control arm received placebo at the same time points.

The primary endpoint of the trial was the time to confirmed platelet normalisation which guides the clinical decision to stop the daily plasma exchanges. The results from this study showed that the group of patients treated with caplacizumab, in conjunction with plasma exchange, achieved confirmed platelet normalisation at more than twice the rate of the group receiving the standard of care plus placebo at any time during the 30-day period after start of study drug, as demonstrated by the hazard ratio of 2.2 (p = 0.013, 95% confidence interval [1.28-3.78]); where the "hazard" is the rate at which  an event occurs, with the event here being confirmed platelet normalisation. Time to confirmed platelet normalisation for patients who had not received a plasma exchange prior to initial dosing with caplacizumab was a median of 3.0 days in the caplacizumab arm compared to a median of 4.9 days in the placebo arm - a potentially clinically meaningful 39% decrease.

The potential protective effect of caplacizumab in the treatment of TTP was also shown by the 73% fewer patients who experienced an exacerbation in the active treatment arm compared to the control group, with 3 (8%) of patients treated with caplacizumab experiencing an exacerbation compared to 11 (28%) treated with placebo. An exacerbation is defined as the recurrence of thrombocytopenia (low platelet count) requiring re-initiation of plasma exchange treatment within 30 days after stopping the initial daily plasma exchanges. Importantly, 81% of caplacizumab treated patients achieved complete remission compared to 46% of placebo treated patients, where "complete remission" is defined as confirmed platelet normalisation together with an absence of exacerbations.

Other news from the department research and development

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance